Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors.
Schalper KA., Carleton M., Zhou M., Chen T., Feng Y., Huang S-P., Walsh AM., Baxi V., Pandya D., Baradet T., Locke D., Wu Q., Reilly TP., Phillips P., Nagineni V., Gianino N., Gu J., Zhao H., Perez-Gracia JL., Sanmamed MF., Melero I.
Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.